Head of Pharma Research & Early Development (pRED) at Roche
John is Global Head of Roche Pharma Research & Early Development (pRED), responsible for directing research and early development activities from target through to Phase II, proof-of-concept studies across all therapeutic areas. He is also a member of Roche’s Corporate Executive Committee, reporting to the company CEO.
Before joining Roche in 2013, John was an accomplished physician-scientist. He served as CEO of one the largest non-profit biomedical research institutes in the US, running a laboratory that generated more than 800 research publications and over 90 patents. John was awarded hundreds of research grants, and his work is among the most highly cited in the world.
John has served on multiple editorial boards for biomedical research journals, and on various advisory committees and boards for biopharmaceutical and biotechnology companies, as well as public and private, non-profit biomedical research organizations.
During his academic career, John held faculty appointments at five different universities. He is a Fellow of the American Association for the Advancement of Science (AAAS) and a recipient of numerous honors and awards for his scientific accomplishments. John is founder or co-founder of several biopharmaceutical and biotechnology companies, and previously served on the board of directors of five publicly listed organizations.